Cargando…

B cell alterations during BAFF inhibition with belimumab in SLE

BACKGROUND: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which exhibits multiple B cell abnormalities including expanded populations of memory B cells and elevated levels of autoantibodies. Belimumab is a monoclonal antibody targeting the B cell cytokine BAFF (a.k.a. BLyS), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramsköld, Daniel, Parodis, Ioannis, Lakshmikanth, Tadepally, Sippl, Natalie, Khademi, Mohsen, Chen, Yang, Zickert, Agneta, Mikeš, Jaromír, Achour, Adnane, Amara, Khaled, Piehl, Fredrik, Brodin, Petter, Gunnarsson, Iva, Malmström, Vivianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412067/ https://www.ncbi.nlm.nih.gov/pubmed/30593436 http://dx.doi.org/10.1016/j.ebiom.2018.12.035

Ejemplares similares

Mass Cytometry Identifies Distinct Lung CD4(+) T Cell Patterns in Löfgren’s Syndrome and Non-Löfgren’s Syndrome Sarcoidosis
por: Kaiser, Ylva, et al.
Publicado: (2017)

Continuous Immune Cell Differentiation Inferred From Single-Cell Measurements Following Allogeneic Stem Cell Transplantation
por: Chen, Yang, et al.
Publicado: (2018)

Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease
por: Stikvoort, Arwen, et al.
Publicado: (2017)

Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study
por: Samuelsson, Isak, et al.
Publicado: (2021)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
por: Kowalczyk-Quintas, Christine, et al.
Publicado: (2018)

Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy
por: Parodis, Ioannis, et al.
Publicado: (2015)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Natural Killer Cell Tolerance Persists Despite Significant Reduction of Self MHC Class I on Normal Target Cells in Mice
por: Brodin, Petter, et al.
Publicado: (2010)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Stereotypic Immune System Development in Newborn Children
por: Olin, Axel, et al.
Publicado: (2018)

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis
por: Zickert, Agneta, et al.
Publicado: (2023)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Achieving symptom relief in patients with myalgic encephalomyelitis by targeting the neuro-immune interface and optimizing disease tolerance
por: Rodriguez, Lucie, et al.
Publicado: (2023)

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
por: Vallerskog, Therese, et al.
Publicado: (2006)

High CD45 expression of CD8+ and CD4+ T cells correlates with the size of HIV-1 reservoir in blood
por: Petkov, Stefan, et al.
Publicado: (2020)

Interferon (IFN)-λ is a potential mediator in lupus nephritis
por: Zickert, Agneta, et al.
Publicado: (2016)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017)

Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations
por: Mobarrez, Fariborz, et al.
Publicado: (2016)

Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
por: Faliti, Caterina E., et al.
Publicado: (2023)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis
por: Itotagawa, Eri, et al.
Publicado: (2022)

Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE
por: Elbagir, Sahwa, et al.
Publicado: (2022)

Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2019)

Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis
por: Friebus-Kardash, Justa, et al.
Publicado: (2019)

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
por: Lenert, Aleksander, et al.
Publicado: (2015)

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
por: Tandler, Claudia, et al.
Publicado: (2020)

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients
por: Escalera, Carlos Rodríguez, et al.
Publicado: (2022)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data
por: D'Cruz, David, et al.
Publicado: (2023)

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19
por: Rodriguez, Lucie, et al.
Publicado: (2020)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

PReS-FINAL-2285: Pediatric non-renal SLE presenting as periorbital edema: response to treatment with belimumab
por: Arabshahi, B
Publicado: (2013)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
por: Bruce, I N, et al.
Publicado: (2016)

Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE
por: Elbagir, Sahwa, et al.
Publicado: (2021)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies
por: Trentin, Francesca, et al.
Publicado: (2018)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25ma51i1ucjn62rg8klgm4e3m5